Christopher P Parrish1, Daniel Har1, J Andrew Bird2. 1. Division of Allergy and Immunology, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9063, USA. 2. Division of Allergy and Immunology, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9063, USA. drew.bird@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. RECENT FINDINGS: Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT. OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.
PURPOSE OF REVIEW: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. RECENT FINDINGS: Data from phase 2 trials for treatment of peanutallergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT. OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergicinfants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.
Authors: Satya D Narisety; Justin M Skripak; Pamela Steele; Robert G Hamilton; Elizabeth C Matsui; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2009-08-08 Impact factor: 10.793
Authors: J Andrew Bird; Jonathan M Spergel; Stacie M Jones; Rima Rachid; Amal H Assa'ad; Julie Wang; Stephanie A Leonard; Susan S Laubach; Edwin H Kim; Brian P Vickery; Benjamin P Davis; Jennifer Heimall; Antonella Cianferoni; Andrew J MacGinnitie; Elena Crestani; A Wesley Burks Journal: J Allergy Clin Immunol Pract Date: 2017-10-31
Authors: V Lombardi; L Van Overtvelt; S Horiot; H Moussu; H Chabre; A Louise; A-M Balazuc; L Mascarell; P Moingeon Journal: Clin Exp Allergy Date: 2008-07-17 Impact factor: 5.018
Authors: Philippe Bégin; Tina Dominguez; Shruti P Wilson; Liane Bacal; Anjuli Mehrotra; Bethany Kausch; Anthony Trela; Morvarid Tavassoli; Elisabeth Hoyte; Gerri O'Riordan; Alanna Blakemore; Scott Seki; Robert G Hamilton; Kari C Nadeau Journal: Allergy Asthma Clin Immunol Date: 2014-02-20 Impact factor: 3.406